Mr. Zdanowski, Chief Technology Officer, is an accomplished leader in cell therapy manufacturing with over 25 years of relevant experience. He has led manufacturing, logistics, QA/QC and process and analytical development groups for stem cell organizations, and led design, construction and validation of facilities for commercial manufacturing for such firms as Pfizer, Bayer and Regeneron. He was most recently Senior VP of BioPharmaceutical Operations for Medeor Therapeutics. Previously, Mr. Zdanowski was VP of GMP Operations for the New York Stem Cell Foundation and VP of Manufacturing for Mesoblast. Mr. Zdanowski has prepared FDA & EU CMC submissions for several late-stage stem cell products, including the BLA supporting the first FDA approval for an allogeneic stem cell therapy product, HemaCord®. He received his MBA from Columbia University and degrees in mechanical engineering and philosophy from the University of Pennsylvania.
